🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the effort against drug-resistant strains of the bacteria, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are increasing worldwide, with data suggesting over 82 million new cases annually. Notably increased rates are reported in Africa and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the context of increasing worldwide cases, escalating drug resistance and the very limited treatment choices currently available.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance found that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Gain Authorization

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists anticipate that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.

“This authorization signifies a significant shift in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Data and Global Access

As per data published in a prominent scientific publication, zoliflodacin eradicated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which involves two antibiotics. The research included nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have expressed optimism. Access to a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for managing the epidemic. This is viewed as essential to reduce the burden of the infection for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.